Dianthus therapeutics to participate in two upcoming investor events

New york and waltham, mass., april 29, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events.
DNTH Ratings Summary
DNTH Quant Ranking